

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ROXANE LABORATORIES, INC.
Petitioner

v.

NOVARTIS AG
Patent Owner

Case IPR2016-01461
U.S. Patent No. 9,006,224

**PETITIONERS' UPDATED MANDATORY NOTICE PURSUANT TO
37 C.F.R. §42.8(b)(1)**

As set forth in the mandatory notice of related matters at page 5 of the Petition of Roxane, Laboratories, Inc. (“Roxane”) in IPR2016-01461 filed on July 19, 2016, Roxane is aware of, *inter alia*, the following related proceeding *Novartis v. Roxane*, C.A. No. 15-424-RGA. The subject of this proceeding includes an abbreviated new drug application (“ANDA”) which was submitted by Roxane.

Roxane has transferred ownership of the ANDA to West-Ward Pharmaceuticals International Limited, having an address at 1 New Burlington Place, London, W1S 2JD, United Kingdom, a subsidiary of Hikma Pharmaceuticals, PLC. Accordingly, pursuant to 37 C.F.R. § 42.8(b)(1) Roxane, in an abundance of caution, identifies West-Ward Pharmaceuticals International Limited as an additional entity that is a real-party-in-interest who, going forward, may have control over this proceeding.

Respectfully submitted,

Dated: January 11, 2017

By: /Marta E. Delsignore/
Marta E. Delsignore (Reg.No. 32,689)
*Counsel for Petitioner Roxane
Laboratories, Inc.*

Case IPR2016-01461
U.S. Patent No. 9,006,224

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 11th day of January, 2017, a true and correct copy of the foregoing **PETITIONERS' UPDATED MANDATORY NOTICE PURSUANT TO 37 C.F.R. §42.8(b)(1)** was served by electronic mail on Patent Owner's lead and backup counsel at the following email address:

Nicholas N. Kallas (Reg. No. 31,530)
Raymond R. Mandra (Reg. No. 34,382)
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104-3800
ZortressAfinitorIPR@fchs.com

By: /Marta E. Delsignore/

Marta E. Delsignore (Reg.No. 32,689)
GOODWIN PROCTER LLP
620 Eighth Avenue
New York, NY 10018
212-813-8822
mdelsignore@goodwinprocter.com

*Counsel for Petitioner
Roxane Laboratories, Inc.*